36 results on '"Giannetti, Matthew P."'
Search Results
2. Mismatch between subjective and objective dysautonomia
3. Cognitive Impairment and Depression in Mastocytosis: A Synthesis of the Literature
4. Mast cell activation syndrome: Current understanding and research needs
5. Drug and Venom Allergy in Mastocytosis
6. Network autonomic analysis of post-acute sequelae of COVID-19 and postural tachycardia syndrome
7. Difficult Cases in Mast Cell Disorders
8. Differential mast cell mediators in systemic mastocytosis and hereditary α-tryptasemia
9. Mast cell disorders are associated with decreased cerebral blood flow and small fiber neuropathy
10. Treatment of systemic mastocytosis: Novel and emerging therapies
11. Hereditary alpha-tryptasemia in 101 patients with mast cell activation–related symptomatology including anaphylaxis
12. Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology
13. Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs
14. Idiopathic Anaphylaxis: A Form of Mast Cell Activation Syndrome
15. Mast cell activation identified through urine mediators
16. Challenges in Drug and Hymenoptera Venom Hypersensitivity Diagnosis and Management in Mastocytosis
17. MPN-524 Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial
18. POSTER: MPN-524 Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial
19. Avapritinib versus Placebo in Indolent Systemic Mastocytosis
20. Exercise-Induced Anaphylaxis: Literature Review and Recent Updates
21. Interleukin-5 Antagonists Usher in a New Generation of Asthma Therapy
22. Outcomes of COVID‐19 vaccination in 323 patients with clonal and non‐clonal mast cell activation disorders
23. Mast cells in lung damage of COVID-19 autopsies:A descriptive study
24. Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation
25. Mast cells in lung damage of COVID‐19 autopsies: A descriptive study
26. COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms
27. Outcomes of COVID‐19 vaccination in 323 patients with clonal and non‐clonal mast cell activation disorders.
28. Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation
29. Distinct Small Intestine Mast Cell Histologic Changes in Patients With Hereditary Alpha-tryptasemia and Mast Cell Activation Syndrome
30. The Leukotriene E 4 Receptor, CysLT 3 r Regulates Airway Chemosensory Brush Cell Expansion
31. Avapritinib Decreased Symptom Burden in Patients With Indolent Systemic Mastocytosis in the Registrational Double-Blind, Placebo-Controlled PIONEER Study.
32. The Leukotriene E4 Receptor, CysLT3r Regulates Airway Chemosensory Brush Cell Expansion
33. Elevated Serum Tryptase Levels during Rituximab Hypersensitivity Reaction
34. Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
35. Mast Cell Disorders Are Associated with Decreased Cerebral Blood Flow And Small Fiber Neuropathy
36. One-day ultrarush desensitization for Hymenoptera venom anaphylaxis in patients with and without mast cell disorders with adjuvant omalizumab
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.